SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Individuals who were a part of the investigators Screen-HF study (NCT00400257) whose BNP level are in the top quintile will be offered participation in this study. Participants will be randomised to receive either spironolactone or placebo for three years. Participants will then be monitored for indications of heart failure. It is anticipated that the medication will reduce the development of heart failure in this group.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Monash University
• Collaborator: National Heart Foundation, Australia
• Treatments: Spironolactone

Criteria

Inclusion Criteria:

1. Was recruited to SCREEN-HF

2. Has provided informed consent

Exclusion Criteria:

1. Uncorrected hyperkalaemia

2. eGFR < 30 ml/min